Raymond James Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Cuts Target Price to $50
Xenon Pharmaceuticals Analyst Ratings
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
H.C. Wainwright Initiates Xenon Pharmaceuticals(XENE.US) With Buy Rating, Announces Target Price $53
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
RBC Capital Sticks to Its Buy Rating for Xenon (XENE)
Press Release: Xenon Expands Leadership Team With Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target
Xenon Pharmaceuticals Analyst Ratings
Buy Rating Affirmed: Xenon Pharmaceuticals' Promising Clinical Trials and Pipeline Advancement
Xenon Pharmaceuticals Analyst Ratings
Xenon Pharmaceuticals Analyst Ratings
Xenon Pharmaceuticals Analyst Ratings
Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating
Xenon Pharmaceuticals Analyst Ratings
Xenon Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
Xenon Pharmaceuticals Analyst Ratings
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk
Buy Rating Justified by Xenon Pharmaceuticals' Advanced Epilepsy Program and Growth Prospects in Neuroscience